Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
Title:
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
Author:
Li, J. Cheng, Y. Bai, C. Xu, J. Shen, L. Li, J. Zhou, Z. Li, Z. Chi, Y. Yu, X. Li, E. Xu, N. Liu, T. Lou, W. Bai, Y. Yuan, X. Wang, X. Yuan, Y. Chen, J. Guan, S. Fan, S. Su, W.